Phase II Study of RAD001 Head and Neck Cancer
Phase II Study of RAD001 for Treatment of Refractory, Recurrent, Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Sponsor: Julie E. Bauman, MD, MPH
Terminated
This trial was terminated. No reason was provided.
Other Squamous Cell Carcinoma of the Head and Neck trials with similar outcome
- NCT05930938 · Phase PHASE3 · Sep 2024
- NCT04459715 · Phase PHASE3 · Sep 2024
- NCT04659369 · Phase PHASE1 · Oct 2023
- NCT03513042 · Nov 2022
- NCT04453046 · Phase NA · Nov 2022
Browse all Squamous Cell Carcinoma of the Head and Neck trials
This PHASE2 trial investigates Squamous Cell Carcinoma of the Head and Neck and is currently terminated or withdrawn. Julie E. Bauman, MD, MPH leads this study, which shows 7 recorded versions since 2010 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Jan 2018 — Jun 2018 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
▶ Show 2 earlier versions
-
Feb 2017 — Jan 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Jan 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Julie E. Bauman, MD, MPH
- Novartis
For direct contact, visit the study record on ClinicalTrials.gov .